Search

Expert opinions for COVID-19 vaccination in patients with non-malignant hematologic diseases

Carlo Dufour, Helen Papadaki, Alan Warren, Colm Bradley, Cristina Mecucci, Jan Palmblad, Cornelia Zeidler, Francesca Fioredda, Sam Salek, Brigitte Schlegelberger and Daniela Guardo, on behalf of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders; Carlo L.

EHA joins ESMO in calling for EU action on shortages of essential medicines

Apr 15 2019

EHA joins ESMO in calling for EU action on shortages of essential medicines

The European Hematology Association (EHA) has endorsed and signed a collective Call to Action, prepared by the European Society for Medical Oncology (ESMO), on shortages of inexpensive, essential…

“Follow your dreams! Go for it!” – Verena Gaidzik, woman in hematology/EHA volunteer

Mar 15 2019

Verena Gaidzik is a physician scientist in the department of Internal Medicine III (Head: Prof. Dr. Hartmut Döhner) at the University Hospital of Ulm. She has board certifications in internal medicine, hematology and oncology as well as palliative medicine.

EHA, in partnership with ISTH, award two fellows to support global educational opportunities

Nov 27 2018

EHA and the International Society on Thrombosis and Hemostasis (ISTH) jointly awarded two joint ISTH-EHA Training Fellowships to Araci Rondon (The Netherlands) and Dianne van der Wal (Australia).

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

Jun 13 2014 Posted in Press releases

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Jun 14 2013

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

Mar 28 2013 Posted in Press releases

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms

Dates: October 12-14, 2017
Location: Budapest, Hungary
Chairs: C Harrison, JJ Kiladjian

EHA and the EHA Scientific Working Group on Myeloproliferative Neoplasms are organizing this EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms.

Harnessing new developments in genomics to improve outcome for children with poor prognosis leukemia

Apr 30 2014 Posted in Press releases

At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.

Meeting Report: European School of Haematology International Conference of Haematological Disorders in the Elderly

Jan 14 2014

The meeting started by reviewing demographic aspects, physiological changes encountered in the elderly, as well as the definition of older and elderly people, frailty and comorbidity.